Kamada, Baxter sales and marketing update

Baxter launched once-weekly Glassia in the U.S. to treat alpha-1 antitrypsin (AAT) deficiency. Kamada granted Baxter exclusive rights to commercialize the IV formulation of human plasma derived AAT ...